Withdrawal Notice
This paper was originally published in Oncotarget Advance Online Publications on 12/26/2017.In compliance with Oncotarget's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Oncotarget internal or any external indexes or archives.
Clinical Research Papers:
EGFR exon 19 deletion is associated with favorable overall survival after first-line icotinib therapy in advanced non-small cell lung cancer patients: a retrospective, multiple-center, real-world study
Chuantao Zhang1,2,*, Helei Hou1,2,*, Xin Cheng3, Dianxia Gong4, Ling Yang5, Haixin Liu5, Wenyong Zhu6, Na Zhou1,2, Yan Zhu5, Ling Chen5, Kewei Liu1,2, Jingjuan Zhu1,2, Hongying Lv1,2, Tianjun Li1,2, Dong Liu1,2, Jing Cong1,2, Man Jiang1,2, Yakun Zhang5, Hualong Yu1,2, Hongsheng Yu1,2 and Xiaochun Zhang1,2
1Qingdao University, Qingdao, Shandong, China
2Department of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
3Department of Medical Oncology, Qingdao Center Medical Group, No. 2 Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
4Department of Medical Oncology, Ju Xian People’s Hospital, Rizhao, Shandong, China
5Department of Medical Oncology, Qingdao Municipal Hospital, No. 3 Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
6Department of Thoracic Surgery, Qilu Hospital of Shandong University, Qingdao, Shandong, China
*These authors contributed equally to this work
Correspondence to:
Xiaochun Zhang, email: [email protected]
Keywords: non-small cell lung cancer; epidermal growth factor receptor mutation; icotinib
Received: September 04, 2017 Accepted: December 15, 2017 Published: December 26, 2017
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23720